Advancing Brain Health Together

A number of innovative research initiatives within the UK are currently advancing our understanding of neurological and psychiatric disorders. At Imperial College London, researchers have identified liraglutide, a drug traditionally used for diabetes and weight loss, as a potential neuroprotective agent for Alzheimer's disease. Their study demonstrated that patients treated with liraglutide experienced nearly a 50% reduction in brain volume loss and a slower decline in cognitive function, suggesting its efficacy in mitigating neurodegenerative processes. Additionally, the Centre for Psychedelic Research at Imperial, led by Professor Dave Nutt and Dr. David Erritzoe, is conducting the world's first clinical and mechanistic study of psilocybin therapy for gambling addiction, aiming to elucidate the brain mechanisms underlying addiction and mental health disorders.

In Scotland, the University of Edinburgh is at the forefront of integrating neuroimaging and genetic research to unravel the complexities of psychiatric disorders. Professor Heather Whalley is leading studies that combine multimodal imaging techniques with genetic data to investigate the mechanisms underlying conditions such as schizophrenia and bipolar disorder. This approach holds promise for identifying biomarkers that could lead to more targeted and effective treatments. Furthermore, the University of Sheffield has launched Midland Pharmaceuticals, a company focused on developing therapeutics for stroke and spinal cord injury. Their lead compound, MLP-1236, targets inflammation in the central nervous system, representing a novel strategy in neurotherapeutic development.

In line with our congress theme, Advancing Brain Health Together, CINP will be working closely with partner and peer group organisations to create a collaborative scientific programme of the highest quality. Notably, SCNP (the Scandinavian College of Neuropsychopharmacology) will be holding its own annual meeting in conjunction with the international congress, whilst several of our affiliated national societies will contribute dedicated symposia.

CINP2026 will serve as a forum for interdisciplinary discussion of recent breakthroughs and developments will incorporate a dedicated track for early career clinicians and researchers, including opportunities to network with global leaders in the field. The congress will bring together experts from research and medical institutions, leading worldwide regulatory authorities and major pharmaceutical firms to create a framework for a cohesive collaboration between academia, industry and governmental institutions toward the development and appropriate use of central nervous system drugs.

We invite you to be part of these discussions and to play your part in the development of our field!